AB Studio is enhancing the potential and scalability of antibody-based therapeutics. There are many different types of antibodies that vary by target antigen, size and functionality. AB Studio is developing complex antibodies with enhanced efficacy, safety, and manufacturability features that have potential applications for treatment of cancer and infectious diseases. AB Studio depends upon computer-aided antibody design (CAAD) for therapeutic antibody discovery, lead selection, engineering, humanization and optimization. Antibodies made by AB Studio have been used in a variety of cases from developing tri-specific antibodies for COVID-19 to the creation of novel “imbalanced” bi-specific antibodies. 

<p>AB Studio is enhancing the potential and scalability of antibody-based therapeutics. There are many different types of antibodies that vary by target antigen, size and functionality. AB Studio is developing complex antibodies with enhanced efficacy, safety, and manufacturability features that have potential applications for treatment of cancer and infectious diseases. AB Studio depends upon computer-aided antibody design (CAAD) for therapeutic antibody discovery, lead selection, engineering, humanization and optimization. Antibodies made by AB Studio have been used in a variety of cases from developing tri-specific antibodies for COVID-19 to the creation of novel “imbalanced” bi-specific antibodies. </p>


Ab Studio

Candid maintains deal momentum with $925M WuXi partnership - FirstWord Pharma

Meet us at PEGS booth 27！😄

Many interesting talks from the 2024 mAbTalk symposium jointly organized by our society and Antibody Therapeutics! The theme of "AntibodyPlus: Bispecific Antibodies and Antibody-Drug Conjugates” highlights the innovations of the field. 
BIG thanks to all the great speakers of this event! Prof. Mitchell Ho （何苗壮）(Founding Editor-in-Chief of Antibody Therapeutics) reviewed the journey of our society's official journal, Antibody Therapeutics; Dr. Yue Liu from Ab Studio introduced the next generation of T cell engager technology; Dr. Stephen Demarest from Tentarix Biotherapeutics talked about the new multispecific assembly technology; Dr.Gerhard Frey from BioAtla, Inc. introduced their conditional ADC platform; Dr. Jianzhong Wen from Merck talked about how to use QSP models to guide ADC design and selection. 

#mab #mabs #antibody #antibodies #antibodyplus #bispecific #bsab #bsabs #bispecificantibody #bispecificantibodies #adc #adcs #antibodydrugconjugate #antibodydrugconjugates #antibodydiscovery #antibodydevelopment #biologics #symposium

See you at AET booth 602. 😄🤝

Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies


              From the singularity community on Reddit: Google DeepMind's AlphaProteo generates novel proteins for biology and health research
            

AB Studio Transforms a Modest Cottage into an Eco-Friendly Multi Generational Home - Inhabitat

Score hot deals on Black Friday! - SheKnows

STUDIO 99 OPENS IN ROGERS PLACE OCTOBER 18 - Rogers Place

Bride Sarah Wilkinson saves for 20 years to wed herself - BBC.com

Angela Schwab (BFA, Ceramics '06) builds space for the arts to thrive - University of Colorado Boulder

Click here for more information


              Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies
            

ABS’ platforms on YouTube:

Computer designed humanized llama VHH library for antibody discovery webinar:
YouTube link: https://lnkd.in/gHEvicnp

Multi-specific therapeutic antibody design webinar:
Development of multi-specific therapeutic antibodies via computer aided design - YouTube

See you in Boston! 😊

Ab Studio Inc. is Hiring: Molecular Biologist – Cloning & Antibody Database Management

Location: Hayward, CA (San Francisco Bay Area)
Job Type: Full-Time

Ab Studio Inc. is seeking a highly motivated and skilled Molecular Biologist to join our growing team. This position offers an exciting opportunity to contribute to cutting-edge therapeutic antibody discovery and engineering efforts.

Key Responsibilities:
	•	Perform molecular cloning, DNA assembly, site-directed mutagenesis, and DNA library construction to support R&D activities.
	•	Develop, manage, and maintain an antibody sequence and structure database to facilitate discovery and optimization projects.
	•	Oversee multiple ongoing projects, ensuring high-quality execution and timely delivery.
	•	Collaborate with cross-functional teams in molecular biology, bioinformatics, and antibody engineering to drive innovation.

Qualifications:
	•	B.Sc. or M.Sc. in Molecular Biology, Biochemistry, Biotechnology, or a related field.
	•	Extensive hands-on experience in molecular cloning, mutagenesis, and DNA library construction.
	•	Proficiency in antibody sequence database development and management.
	•	Strong organizational skills with a proven ability to manage multiple projects in a fast-paced research environment.
	•	Excellent problem-solving abilities and attention to detail.

Why Join Us?

At Ab Studio, we combine AI/ML/computational design (CAAD) with traditional antibody discovery to develop next-generation therapeutics. Join a forward-thinking and collaborative team at the forefront of biotechnology innovation. We offer a competitive salary and benefits package in a dynamic work environment.

How to Apply:

Interested candidates should submit a CV and cover letter to abstudio.info@antibodystudio.com.

Be part of the future of therapeutic antibody development — Join us in advancing biotechnology innovation!

Tiny prefab timber cabin in New Zealand designed to serene art studio - Inhabitat

Attending SynBioBeta this week, where the theme “AI and Synthetic Biology” extends beyond synthetic biology into AI-driven drug design and clinical trial optimization. The industry consensus is clear: AI can significantly accelerate drug discovery when combined with traditional technologies, but can’t fully replace them.

At Ab Studio, we’ve applied AI and computer-aided design (CAAD) since 2017 to optimize therapeutic antibodies and engineer multi-specifics from IgGs and VHHs. Our lead candidates, CND261 (CD20/CD3) and GB263T (EGFR/c-Met/c-Met), have both entered the clinic through our partners and demonstrated proof-of-concept.

We’ll be at PEGS Boston with a booth—come by to explore how our tech can help solve your toughest biologics R&D challenges. See you in Boston!

Candid Therapeutics to strengthen TCE pipeline through strategic collaborations - BioWorld Online

Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications


              Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications
            


                Careers with Us | AB Studio
              

Read our paper

Candid continues dealmaking spree for TCEs in trio of new partnerships - FirstWord Pharma

We’d like to spotlight this excellent research article published in Antibody Therapeutics with the title of “A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies”. The computationally designed novel ETYY mutations improve heterodimer formation in multi-specific antibodies while preserving the functional and physicochemical properties. This could greatly enhance the large-scale manufacturability and ease of purification for multi-specific antibodies for which heterodimerization is necessary. The corresponding author is Dr. Yue Liu at Ab Studio. The following picture was selected as cover picture of the issue. Open access to this paper at:
https://lnkd.in/eUXaj5aJ

Antibody Therapeutics is the official journal of Chinese Antibody Society, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. 
https://lnkd.in/gsTu_U2

#antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics


              Third Rock and Arie Belldegrun’s firm come together for CD20/CD3 bispecific out of China
            

Profiles in Design: AB Design Studio - The Santa Barbara Independent

Felixstowe woman's wedded bliss one year after marrying herself - BBC.com

Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors

 AbbeyCross Emerging Market FX payments platform hits key milestone: Launch of ABX Studio with US Tier 1 Bank 

HIT launches Angelina Ballerina dance academy - Kidscreen

Candid Therapeutics unwraps three new collaborations to discover and develop T-cell engager antibodies - Fierce Biotech

Angelina Ballerina Dance Program Comes to U.S. - License Global

Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications - Business Wire


              1272P - Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
            

Sarah Wilkinson: Menya uno mugeni yamaze imyaka 20 yegeranya uburyo kugira yirongore - BBC.com

Ab Studio

Business:

About: